For years, healthcare has been one of the most profitable sectors in industry. However the world is changing, and fast.Generics …
GlaxoSmithKline suffered a hit in the US during the third quarter of the year, with sales down 12% to £2.14 …
Profits at Johnson & Johnson have risen in the third quarter, despite deep cuts into pharma sales caused by new …
US pharmaceutical company Hospira has acquired worldwide rights to a biogeneric version of Amgen's neutropenia treatment Neupogen (filgrastim) in a …
UK contract research organisation Cambridge Regulatory Services has teamed up with one of its Indian counterparts – SIRO Clinpharm – …
Mumbai-based generics manufacturer Cipla is to begin making biosimilars, generic substitutable versions of branded biologic drugs. It plans to do …
The practice of branded drugmakers paying rivals to keep generics off the market after product patent expiry – known as …
Former US President Bill Clinton has brokered major new deals with Pfizer and Mylan to cut the price of tuberculosis …
Deals allowing US pharma companies to pay generics competitors to delay the launch of rival products should be ended, according …
The European Union's competition watchdog has declared a crackdown on pharma industry competition, promising scrutiny of deals which it says …
Japan has approved its first biosimilar medicine – the recombinant human growth hormone somatropin from Novartis' generic arm Sandoz. The …

GlaxoSmithKline will increase its reach into emerging markets with a new deal to co-market generics with Dr. Reddy’s.The Indian company …
Moves to make it easier for biosimilars to be approved in the US are gaining momentum.The pharma industry has conceded …
Sandoz, the generics arm of Novartis, is to acquire the generic injectables business of Austrian company EBEWE Pharma.The deal, which …
Pfizer has expanded its presence in the generics market with deals that see it licence 75 products from two Indian …